Neurobiological To Revive Viprinex Stroke Trials Following Empire Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
New Phase III trials for Abbott's former anticoagulant will be based on meta-analyses of previous Phase II and III trials of the pit viper venom-derived agent, Neurobiological Technologies says. Empire licensed Viprinex from Abbott in 2002.